Our Strategy Company Overview INmune Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction are primary drivers of pathology. Lead Program : CORDStrom for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) using CORDStrom, our proprietary, ...
Q2 FY2026 — expected 2026-09-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001213900-26-036370 | EDGAR | 60K words |
| 2025-03-27 | 2024-12-31 | 0001013762-25-003354 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001213900-24-027206 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0001213900-23-016875 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001213900-22-010573 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001213900-21-013456 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001213900-20-005916 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001640334-19-000466 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001213900-25-104141 | EDGAR | 20K words |
| 2025-08-07 | 2025-06-30 | 0001213900-25-073077 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001213900-25-041072 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001213900-24-092861 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001213900-24-064076 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001213900-24-041286 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0001213900-23-082167 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001213900-23-064057 | EDGAR | — |
| 2023-05-03 | 2023-03-31 | 0001213900-23-035972 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0001213900-22-068637 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001213900-22-044453 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001213900-22-024226 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-27 | 0001213900-26-021120 | EDGAR | 5K words |
| 2026-02-23 | 0001213900-26-019321 | EDGAR | — |
| 2026-02-19 | 0001213900-26-018396 | EDGAR | — |
| 2026-02-13 | 0001213900-26-016385 | EDGAR | — |
| 2026-01-27 | 0001213900-26-008204 | EDGAR | — |
| 2025-12-23 | 0001213900-25-125282 | EDGAR | — |
| 2025-12-19 | 0001213900-25-123880 | EDGAR | — |
| 2025-12-10 | 0001213900-25-120067 | EDGAR | — |
| 2025-12-08 | 0001213900-25-119217 | EDGAR | — |
| 2025-12-05 | 0001213900-25-118699 | EDGAR | — |
344 total filings indexed. 314 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001711754 |
| Ticker | INMB |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | NV |
| Website | https://www.inmunebio.com |
| Listed | 2019-02-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report